Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Meeting Calendar
  3. Past Meetings
  4. ESMO Breast Cancer 2024
  5. Satellite Symposia Webcasts

Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer

Closing and key takeaways

Date

16 May 2024

Session

Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer

Presenters

Wolfgang Janni

Authors

W. Janni

Author affiliations

  • Ulm Medical University, Ulm/DE

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and introduction

Presenter: Wolfgang Janni

Session: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer

Resources:

Webcast

Unmet need in HR+/HER2- early breast cancer

Presenter: Wolfgang Janni

Session: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.